Abstract: Antibodies, polypeptides, and polynucleotides are provided for the detection, prevention, amelioration and treatment of diseases caused by Actinobacillus actinomycetemcomitans.
Type:
Grant
Filed:
November 28, 2001
Date of Patent:
May 30, 2006
Assignee:
University of Florida Research Foundation
Inventors:
Martin Handfield, Jeffrey Daniel Hillman, Ann Progulske-Fox
Abstract: This invention pertains to the discovery that the human NELL-1 gene induces or upregulates bone mineralization. The NELL-1 gene or gene product thus provides a convenient target for screening for modulators of bone mineralization. In addition, NELL-1 can be used to facilitate repair of bone fractures and/or to generally increase bone density.
Type:
Grant
Filed:
October 5, 1999
Date of Patent:
May 30, 2006
Assignee:
The Regents of the University of California
Abstract: The present invention provides for methods of treating cardiovascular diseases in a mammal. The methods include a step of administering an effective amount of a botulinum toxin directly to a blood vessel of a mammal thereby treating a cardiovascular disease.
Abstract: A nucleic acid-bound polypeptide produced by binding a nucleic acid to a polypeptide, a method of producing the nucleic acid-bound polypeptide, and applications of the nucleic acid-bound polypeptide, including immunoassays for an antigen or antibody, such as an agglutination immunoassay are provided.
Abstract: A method and composition for the passive immunization of patients infected with or susceptible to infection from Staphylococcus bacteria such as S. aureus and S. epidermidis infection is provided that includes the selection or preparation of a donor plasma pool with high antibody titers to carefully selected Staphylococcus adhesins or MSCRAMMs, or fragments or components thereof, or sequences with substantial homology thereto. The donor plasma pool can be prepared by combining individual blood or blood component samples which have higher than normal titers of antibodies to one or more of the selected adhesins or other proteins that bind to extracellular matrix proteins, or by administering carefully selected proteins or peptides to a host to induce the expression of desired antibodies, and subsequently recovering the enhanced high titer serum or plasma pool from the treated host.
Type:
Grant
Filed:
March 7, 2002
Date of Patent:
May 16, 2006
Assignee:
Inhibitex, Inc.
Inventors:
Joseph M. Patti, Timothy J. Foster, Magnus Hook
Abstract: The present invention relates to live attenuated Salmonella strains comprising a first attenuating mutation, that are not capable of making functional RecA. The invention also relates to these bacteria for use in vaccines. Furthermore, the invention relates to vaccines based upon these bacteria, to the use of such bacteria in the manufacture of vaccines and to methods for the preparation of such vaccines.
Type:
Grant
Filed:
November 15, 2001
Date of Patent:
May 16, 2006
Assignee:
Akzo Nobel N.V.
Inventors:
Petrus Johannes Maria Nuijten, Maarten Hendrik Witvliet
Abstract: The present invention provides a method of treating or preventing inflammation in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B. The present invention also provides a method of decreasing the activity of interferon gamma in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B. Further provided is a method of decreasing the activity of IL-12 in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B. Additionally, the present invention provides a method of treating or preventing a Th1 T-cell mediated autoimmune disorder in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B.
Type:
Grant
Filed:
November 9, 2000
Date of Patent:
May 9, 2006
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Warren Stober, Ivan J. Fuss, Brian L. Kelsall, Monica Boirivant
Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Enterobacter cloacae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
Type:
Grant
Filed:
February 18, 1999
Date of Patent:
May 9, 2006
Assignee:
Genome Therapeutics Corporation
Inventors:
Keith G. Weinstock, Craig Deloughery, David Bush
Abstract: The invention provides mutant forms of pore-forming toxins. These mutant toxins may be used in vaccines for the prevention of bacterial infection. Additionally, dominant negative mutants may be administered as therapeutics for the treatment of bacterial infection.
Type:
Grant
Filed:
May 4, 2001
Date of Patent:
May 2, 2006
Assignee:
President and Fellows of Harvard College
Abstract: The invention provides FabK polypeptides and polynucleotides encoding FabK polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are preferred methods for utilizing FabK polypeptides and polynucleotides as diagnostic reagents and in diagnostic assays to screen for microbial infections in organisms and infestations in materials.
Type:
Grant
Filed:
November 26, 2002
Date of Patent:
April 25, 2006
Assignee:
Affinium Pharmaceuticals, Inc.
Inventors:
Walter E. DeWolf, Jr., David John Payne, Nicola Gail Wallis, Joshua M. West
Abstract: The method for the diagnosis of Helicobacter pylori infection by the oral administration of defined amounts of 13C-labeled urea and examination for 13C content of blood samples removed at a defined time is effected by a) removing from 0.1 to 0.6 ml of capillary blood from the finger or ear lob of a patient or venous blood of a patient, in both cases with an empty stomach before the beginning of the test; b) administering an exact amount of from 10 to 50 mg of 13C-urea in aqueous solution with a pH value of 2 to 4 to the patient; c) again removing capillary or venous blood exactly after 10 to 15 min from the administration; and d) determining the 13C content of the blood samples by isotope ratio mass spectrometry (IRMS), and deducing the presence of Helicobacter pylori from the increase of the 13C values.
Abstract: The present invention relates generally to therapeutic compositions for the treatment and/or prophylaxis of intestinal disease conditions in animals and birds caused or exacerbated by Lawsonia intracellularis or similar or otherwise related microorganism. In particular, the present invention provides a novel gene derived from Lawsonia intracellularis which encodes an immunogenic hemolysin peptide, polypeptide or protein that is particularly useful as an antigen in vaccine preparation for conferring humoral immunity against Lawsonia intracellularis and related pathogens in animal hosts. The present invention is also directed to methods for the treatment and/or prophylaxis of such intestinal disease conditions and to diagnostic agents and procedures for detecting Lawsonia intracellularis or similar or otherwise related microorganisms.
Type:
Grant
Filed:
May 11, 2000
Date of Patent:
April 18, 2006
Assignees:
Pfizer Products, Inc., Agriculture Victoria Services Pty. Ltd., Pig Research and Development Corporation
Inventors:
Michael Panaccio, Everett Lee Rosey, Detlef Hasse, Robert Gerard Ankenbauer
Abstract: The DNA of the invention are characterised in that they concern the whole or part of genes, with their reading frame, to be found in Neisseria meningitidis, but not in Neisseria gonorrhoeae, or in Neisseria lactamica except the genes involved in the biosynthesis of the polysaccharide capsule, frp A, frp C, opc, por A, rotamase the sequence IC1106, IgA protease, pilline, pilC, transferrin binding proteins and opacity proteins. The invention also concerns the polypeptides corresponding to these DNA and the antibodies directed against these polypeptides. It is applicable in the prevention and the detection of meningococcus induced infections and meningitis.
Type:
Grant
Filed:
August 14, 2001
Date of Patent:
April 18, 2006
Assignees:
Institut National de la Sante et de la Recherche Medicale (I.N.S.E.R.M.), Max-Planck-Gesellschaft zur Forderung des Wessenschaften E.V., Smithkline Beecham
Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) AMA-1 ectodomain. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant AMA-1 is useful as a diagnostic reagent, for use in antibody production, and as a protein for use alone, or as part of, a vaccine to prevent malaria.
Type:
Grant
Filed:
October 15, 2002
Date of Patent:
April 18, 2006
Assignee:
The United States of America as represented by the Secretary of the Army
Inventors:
David E. Lanar, Sheetij Dutta, Lisa A. Ware, Lalitha P. V. Nair
Abstract: Bacteria and in particular pathogenic bacteria are treated in a manner which alters the bacteria's native level or activity of DNA methyltransferase (Dam). The alteration results in a change in the bacteria's native level of methylation of adenine in a GATC tetranucleotide which inhibits virulence of the bacteria. Thus, compounds which inhibit proliferation of bacteria are useful in treating bacterial infections.
Type:
Grant
Filed:
August 9, 2001
Date of Patent:
April 11, 2006
Assignee:
Regents of the University of California
Inventors:
Michael J. Mahan, Douglas M. Heithoff, David A. Low, Robert L Sinsheimer
Abstract: A host is immunized against infection by a strain of Chlamydia by initial administration of an attenuated bacteria harbouring a nucleic acid encoding a Chlamydia protein followed by administration of a Chlamydia protein in ISCOMs. This procedure enables a high level of protection to be achieved.
Abstract: This invention provides isolated polynucleotides that encode the MurC protein of Pseudomonas aeruginosa. Purified and isolated MurC recombinant proteins are also provided. Nucleic acid sequences which encode functionally active MurC proteins are described. Assays for the identification of modulators of the of expression of murC and inhibitors of the activity of MurC, are also provided.
Type:
Grant
Filed:
September 11, 2000
Date of Patent:
April 4, 2006
Assignee:
Merck & Co., Inc.
Inventors:
Mohamend El-Sherbeini, Barbara Azzolina
Abstract: The invention provides a novel process of lignin degradation using a consortium of bacteria. To date, biodegradation of lignin has been centered to fungi only. Degradation of lignin by bacteria confer a new understanding that may be of tremendous industrial significance. This invention also discloses the isolation and acclimatization of ligninolytic bacteria from a specific site.
Type:
Grant
Filed:
March 21, 2003
Date of Patent:
April 4, 2006
Assignee:
Council of Scientific & Industrial Research
Abstract: The present invention relates to antigens of Moraxella, in particular, Moraxella bovis, nucleic acid sequences encoding these antigens and formulations for use in raising an immune response against Moraxella.
Type:
Grant
Filed:
August 31, 2000
Date of Patent:
March 28, 2006
Assignees:
Commonwealth Scientific and Industrial Research Organisation, The University of Melbourne
Inventors:
Jacinta Farn, Richard Strugnell, Jan Tennent
Abstract: The present invention relates to a vaccine for the prevention of lactic acidosis in a vertebrate, said vaccine comprising at least one isolated microorganism, or fragment or fragments thereof, wherein said microorganism is capable of producing lactic acid within the gut of said vertebrate, and wherein said microorganism is selected from the group consisting of: Clostridium-like species, Prevotella-like species, Bacteroides-like species, Enterococcus-like species, Selenomonas species, non-dextran slime producing Streptococcus species and non-slime producing lactic acid bacterial isolates.